Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited successfully issued 125 million new shares to select investors, as part of a strategy shift to focus exclusively on their iNKT cell therapy platform, while ongoing commercial disputes regarding the ZolpiMist product continue without a resolution or clear financial implications for the company.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
